Clinical Trial Update: Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib in combination with docetaxel for prostate cancer that progressed after hormone therapy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-02-17